Although KMT2A rearrangement has been identified as a high-risk marker in both ALL and AML, it is believed that the specific fusion partner plays an indispensable role in pathogenesis and can influence the outcome to some extent [14, 15]. The gene discussed is KMT2A; the disease is acute myeloid leukemia.